Login to Your Account



Other News To Note


Wednesday, April 10, 2013
• biOasis Technologies Inc., of Vancouver, British Columbia, said BT2111, a brain-penetrating conjugate of trastuzumab (Herceptin, Roche AG) and its Transcend vector designed to treat brain metatastsis of HER2-positive tumors, has moved into the next stage of preclinical development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription